Genmab Appoints Annarie Lyles as Head of Business Development
News Jan 04, 2006
Genmab A/S has announced the appointment of Annarie Lyles, Ph.D. as Head of Business Development with effect from January 1, 2006.
Dr. Lyles was previously appointed Vice President, Business Development at Genmab in June 2005.
Dr. Lyles replaces Dr. Ernst Schweizer, who has retired from his position as Head of Business Development. Dr. Schweizer remains a member of the Genmab Board of Directors.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.